Filing Details
- Accession Number:
- 0001209191-20-013025
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-26 16:32:54
- Reporting Period:
- 2020-02-24
- Accepted Time:
- 2020-02-26 16:32:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1735944 | Reshma Kewalramani | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp And Cmo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-24 | 2,898 | $239.23 | 30,260 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2020-02-25 | 893 | $229.72 | 29,367 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 450 | $230.88 | 28,917 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 440 | $232.35 | 28,477 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 660 | $234.41 | 27,817 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 340 | $235.36 | 27,477 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 320 | $236.71 | 27,157 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 420 | $238.28 | 26,737 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 111 | $239.13 | 26,626 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $229.72 (range $229.23 to $230.17).
- Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $230.88 (range $230.48 to $231.38).
- Open market sales reported on this line occurred at a weighted average price of $232.35 (range $232.14 to $233.08).
- Open market sales reported on this line occurred at a weighted average price of $234.41 (range $233.90 to $234.80).
- Open market sales reported on this line occurred at a weighted average price of $235.36 (range $235.13 to $235.56).
- Open market sales reported on this line occurred at a weighted average price of $236.71 (range $236.31 to $237.24).
- Open market sales reported on this line occurred at a weighted average price of $238.28 (range $238.01 to $238.54).
- Open market sales reported on this line occurred at a weighted average price of $239.13 (range $239.13 to $239.14).
Billionaire Hedge Funds
